|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
A10BJ02
|
|
gptkbp:chemicalFormula
|
C172H265N43O51
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:drugClass
|
GLP-1 receptor agonist
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:liraglutide
|
|
gptkbp:halfLife
|
13 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Victoza
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:mechanismOfAction
|
slows gastric emptying
decreases glucagon secretion
increases insulin secretion
|
|
gptkbp:molecularWeight
|
3751.2 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
nausea
vomiting
diarrhea
pancreatitis
|
|
gptkbp:storage
|
2°C to 8°C (refrigerated)
|
|
gptkbp:usedFor
|
reducing risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
improving glycemic control
|
|
gptkbp:website
|
https://www.victoza.com/
|
|
gptkbp:bfsParent
|
gptkb:Novo_Nordisk
|
|
gptkbp:bfsLayer
|
6
|